Tag
A large cohort study found that health plan disenrollment after starting buprenorphine or naltrexone for opioid use disorder was linked to higher all-cause and overdose mortality, highlighting the importance of continuous coverage and treat
The ED INNOVATION trial reveals that 7-day extended-release injectable buprenorphine is safe and as effective as sublingual formulations for treatment engagement, offering significant benefits in craving reduction and patient satisfaction e
This randomized clinical trial compares 100-mg and 300-mg maintenance doses of extended-release buprenorphine. While overall efficacy was similar, the 300-mg dose significantly improved abstinence among patients with high-frequency fentanyl
This randomized clinical trial compares 100-mg versus 300-mg maintenance doses of extended-release buprenorphine. While overall efficacy was similar, the 300-mg dose significantly improved abstinence rates among heavy fentanyl users, offeri
This nationwide cohort study reveals higher discontinuation rates of buprenorphine than methadone during pregnancy and up to one year postpartum, highlighting significant challenges in treatment retention for opioid use disorder in pregnant
A secondary analysis of four randomized trials reveals that additional behavioral therapy does not significantly improve opioid abstinence, retention, or functional outcomes when added to buprenorphine and medical management in opioid use d
